Human medicines European public assessment report (EPAR): Tremelimumab AstraZeneca, tremelimumab, Carcinoma, Non-Small-Cell Lung, Date of authorisation: 20/02/2023, Revision: 1, Status: Authorised

Human medicines European public assessment report (EPAR): Teriparatide Sun, teriparatide, Osteoporosis;Osteoporosis, Postmenopausal, Date of authorisation: 18/11/2022, Revision: 1, Status: Authorised

Levobupivacaine : List of nationally authorised medicinal products - PSUSA/00001848/202212

Timetable: Safety referral (Article 107i, urgent Union procedure)

Timetable: Safety referral (Article-20 and Article-31 pharmacovigilance)

Timetable: Non-safety referrals

National Innovation Offices Contacts

EU-Innovation Network Workplan 2023

Summary of opinion: Loxitab,meloxicam, 07/09/2023, Positive

Summary of opinion: Poulvac Procerta HVT-IBD,turkey herpes virus, strain FC-126, expressing infectious bursal disease virus VP2 protein, live, 07/09/2023, Positive